MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Techno-Science.net on MSN
When a synthetic tiny fiber self-replicates in the brain
Multiple system atrophy (MSA) is a rare and severe neurodegenerative disease, caused by the massive and rapid accumulation of ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
VALBY, Denmark, May 8, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a potential ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Taking lipoic acid failed to ease progressive MS symptoms in a clinical trial, but the antioxidant showed signs of slowing ...
Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.
9don MSN
Using over-the-counter antioxidant to treat progressive multiple sclerosis shows mixed results
The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback